EUVIMEDEUVIMED entdecken
Open Access

Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease

Sara Y Tartof, Negar Aliabadi, Gabriella Goodwin, Jeff Slezak, Vennis Hong, Bradley Ackerson, Qing Liu, Sally Shaw, Sabrina Welsh, Julie A Stern, Banshri Kapadia, Brigitte C Spence und 11 weitere

JAMA Network Open · 13.12.2024 · 7 (12) · e2450832

DOI: 10.1001/jamanetworkopen.2024.50832 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 13.12.2024. Verfasst von Sara Y Tartof und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Vaccine Efficacy, Respiratory Syncytial Virus Vaccines. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Clinical trials have demonstrated high vaccine efficacy (VE) against lower respiratory tract disease (LRTD) but enrolled a smaller proportion of persons aged 75 years or older and those with comorbidities than seen in highest-risk populations in clinical practice settings. Additionally, VE against respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits is not yet fully described.

Objective

To estimate Respiratory Syncytial Virus Prefusion F (RSVpreF) effectiveness in older adults. Design, Setting, and Participants This was a retrospective case-control study with a test negative design. Cases were adults aged 60 years or older with hospitalizations or ED visits at Kaiser Permanente of Southern California for LRTD from November 24, 2023, to April 9, 2024, who had respiratory swabs collected and tested for RSV. Two control definitions were prespecified: (1) strict controls included RSV-negative LRTD events that were negative for human metapneumovirus, SARS-CoV-2, and influenza, and positive for a nonvaccine preventable cause (primary) and (2) broad controls included all RSV-negative LRTD events (sensitivity analysis). Enhanced specimen collection was conducted to salvage clinical respiratory swabs not tested for RSV during routine care. Data were analyzed from May to September 2024. Exposure RSVpreF vaccine receipt during the first RSV season after licensure and 21 or more days before LRTD event. Main outcomes and measures Estimated VE against RSV-related LRTD hospitalization or ED visit.

Results

A total of 5714 LRTD-related hospitalizations or ED encounters with RSV testing results were included. The mean (SD) age was 77.4 (9.5) years; 3092 (54.1%) were female; 658 (11.5%) were non-Hispanic Asian or Pacific Islander, 1788 (31.3%) were Hispanic, 936 (16.4%) were non-Hispanic Black, and 2266 (39.7%) were non-Hispanic White; 860 (15.1%) were immunocompromised; and 5415 (94.8%) had 1 or more Charlson comorbidity. Using strict controls, estimated adjusted VE was 89% (95% CI, 52%-97%). Using broad controls, estimated adjusted VE was 87% (95% CI, 48%-97%). Conclusions and Relevance In a high-risk, general population, RSVpreF vaccination conferred protection against RSV-related LRTD in the hospital and ED settings among US adults aged 60 years or older, the majority of whom were aged 75 years or older and had comorbidities. These data support use of this vaccine in older adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsVaccine EfficacyRespiratory Syncytial Virus VaccinesHumansAgedFemaleMaleRetrospective StudiesCase-Control StudiesCaliforniaAged, 80 and overMiddle AgedHospitalizationRespiratory Syncytial Virus, HumanRespiratory Tract InfectionsCOVID-19Emergency Service, Hospital

Substanzen

Respiratory Syncytial Virus Vaccines

Autor:innen und Institutionen

  • Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena.
  • Pfizer, Inc, Collegeville, Pennsylvania.
  • Division of Epidemiology and Division of Infectious Diseases and Vaccinology, School of Public Health, and Center for Computational Biology, College of Engineering, University of California, Berkeley.

Zitieren

APA

Tartof, S. Y., Aliabadi, N., Goodwin, G., Slezak, J., Hong, V., Ackerson, B., Liu, Q., Shaw, S., Welsh, S., Stern, J. A., Kapadia, B., Spence, B. C., Lewnard, J. A., Davis, G. S., Aragones, M., Dutro, M., Chilson, E., Gonzalez, E., Hubler, R., …, & Begier, E. (2024). Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease. JAMA Network Open, 7(12), e2450832. https://doi.org/10.1001/jamanetworkopen.2024.50832

Vancouver

Tartof SY, Aliabadi N, Goodwin G, Slezak J, Hong V, Ackerson B, et al. Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease. JAMA Network Open. 2024;7(12):e2450832. doi:10.1001/jamanetworkopen.2024.50832

BibTeX
@article{Tartof2024,
  author = {Tartof, Sara Y and Aliabadi, Negar and Goodwin, Gabriella and Slezak, Jeff and Hong, Vennis and Ackerson, Bradley and Liu, Qing and Shaw, Sally and Welsh, Sabrina and Stern, Julie A and Kapadia, Banshri and Spence, Brigitte C and Lewnard, Joseph A and Davis, Gregg S and Aragones, Michael and Dutro, Michael and Chilson, Erica and Gonzalez, Elisa and Hubler, Robin and Chia, Brandon and Jodar, Luis and Gessner, Bradford D and Begier, Elizabeth},
  title = {Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Lower Respiratory Tract Disease},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {12},
  pages = {e2450832},
  doi = {10.1001/jamanetworkopen.2024.50832}
}
Kostenlos starten →